Vical dives as Allovectin terminated on 'conclusive failure'
This article was originally published in Scrip
Executive Summary
Vical's Phase III trial of Allovectin (velimogene aliplasmid), an investigational intratumoral cancer immunotherapy in patients with metastatic melanoma, has failed to meet its primary endpoint.